Arthrosamid® Hydrogel Injections
Overview
Arthrosamid® is an advanced, long-acting injectable polyacrylamide hydrogel (iPAAG) designed to provide multi-year pain relief in patients with knee osteoarthritis.
Unlike traditional injectables that are absorbed or broken down by the body, Arthrosamid® forms a non-biodegradable, permanent implant within the joint, acting as a soft, cushioning scaffold that stabilises and improves the joint environment.
This makes it a premium non-surgical option for patients who have not achieved lasting relief from hyaluronic acid (HA) or platelet-rich plasma (PRP) treatments — and who wish to delay or avoid joint replacement surgery.
What It Treats
-
Moderate to advanced knee osteoarthritis (OA)
-
Patients under 70 years aiming to postpone or avoid joint replacement
-
Individuals with limited benefit from HA, PRP, or combination injections
-
Those seeking durable, multi-year relief without surgery
How It Works
A single 6 mL injection of Arthrosamid® is administered under ultrasound guidance to ensure precise placement within the knee joint.
Once injected, the non-resorbable hydrogel integrates within the synovial membrane, acting as a mechanical scaffold and reducing fluid buildup (effusion) and inflammation.
This stabilisation improves the joint’s internal environment, helping to:
-
Relieve chronic pain and stiffness
-
Enhance movement and physical function
-
Maintain results for 3–4 years or more
Because Arthrosamid® is non-biodegradable, its structure remains intact long-term, providing consistent cushioning and pressure distribution with every movement.
Benefits & Limitations
Benefits
-
Multi-year durability – sustained pain relief and mobility improvement for up to 3–4 years or more
-
Single injection – long-term benefits from one minimally invasive procedure
-
Delays or reduces need for surgery such as total knee replacement
-
Improves quality of life through reduced pain and greater physical activity
-
Safe and CE-marked medical device with over 20 years of hydrogel technology background
-
Can be performed outpatient under local anaesthetic and ultrasound guidance
Limitations
-
Strict procedural requirements – oral antibiotics must be taken 1–2 hours prior to injection to prevent infection
-
Not suitable for all patients – requires careful clinical screening
-
Permanent implant means infection management is more complex if it occurs
-
Results depend on joint condition – optimal outcomes seen in mild to moderate OA
-
Currently under evaluation by NICE (UK regulatory body)
Side Effects & Considerations
-
Post-injection flare – temporary swelling or discomfort can occur within 6 weeks after treatment
-
Joint infection risk – extremely rare but serious; mitigated by mandatory antibiotic prophylaxis
-
Temporary stiffness or mild effusion may be felt in the days following treatment
-
Allergic reaction to hydrogel or anaesthetic is possible but uncommon
-
Not suitable for:
• Patients with active infection or fever
• Recent knee surgery (within 6 months)
• Bleeding disorders or anticoagulant therapy
• Autoimmune conditions (e.g., uncontrolled rheumatoid arthritis)
• Pregnant or breastfeeding patients
Procedure & Aftercare
-
The procedure is performed in a sterile outpatient setting using local anaesthetic and ultrasound guidance.
-
The clinician injects 6 mL of Arthrosamid® hydrogel directly into the joint cavity.
-
Patients rest for 20–30 minutes post-procedure before discharge.
-
Take prescribed oral antibiotics before the procedure as directed.
-
Do not drive immediately after treatment.
-
Avoid strenuous or high-impact activities (e.g., running, squatting, or long walks) for 2 weeks.
-
Apply ice packs intermittently if mild swelling occurs.
-
Monitor for any signs of infection (swelling, warmth, redness) and report immediately if present.
-
Full benefit typically develops gradually over 6–12 weeks and can last for years.
